<DOC>
	<DOCNO>NCT00647465</DOCNO>
	<brief_summary>Influenza vaccination reduces morbidity mortality associate influenza infection risk group include elderly individual impair immune response , totally protective recipient . Cytokines include type I interferon know play key role innate immune response virus infection induction primary adaptive-immune response . Thus , evaluate safety sublingual administration IFNa effect immune response influenza vaccination randomize double-blind placebo control study elderly institutionalized individual .</brief_summary>
	<brief_title>Effect Interferon Alpha Citizen Sub-Lingual Way Humoral Immunizing Answer</brief_title>
	<detailed_description>The protection afford commonly use influenza sub-unit vaccine think due principally production antibody viral haemagglutinin . The haemagglutination inhibitory ( HAI ) antibody titer generally use surrogate marker protection HAI antibody titer 1:40 great consider confer protection . This attain , however , 50 % elderly subject . Thus , unmet need effective non-toxic adjuvant capable enhance antibody response influenza vaccine . Type I IFNs show induce B-lymphocytes differentiate antibody produce plasma cell necessary production specific polyclonal IgGs response influenza infection . Furthermore , type I IFNs increase primary antibody response soluble antigen vivo , increase production IgG sub-classes . Type I IFNs play key role adjuvant-induced Th1 response . Thus , evaluate safety sublingual administration IFNa effect immune response influenza vaccination.Institutionalized subject , age 75 , randomly assign two group receive double-blind fashion either 107 IU Intron ATM 1 ml isotonic saline 1 ml saline alone ( placebo ) administer sublingually . Interferon placebo retain mouth least 30 second prior ejection . All subject vaccinate , within 30 minute , single intramuscular injection ( im ) influenza vaccine ( InfluvacTM , Solvay Pharma , France ) . The primary objective study compare immunogenicity percentage subject increase 4 fold HAI antibody titer day 21 ) obtain IFN treat group relative placebo treat group . The secondary objective compare mean HAI antibodies titer obtain two group day 21 ; specific IgG , IgG2a , IgG2a/IgG1 ratio secretory IgA titer 2 group ; specific secretory IgA titer saliva ; durability protective HAI antibodies titer 3 6 month vaccination safety sublingual administration IFNa .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Subjects age 75 , institutionalize Subjects inform objective study give write consent . Subjects receive least one prior influenza vaccination previous 5 year . Subjects vaccinate influenza 2005 vaccination campaign . Individuals severe disease , include neoplasia , autoimmune disease , type I diabetes concomitant treatment glucocorticoid immunosuppressive drug splenectomy tonsillectomy incapacity open mouth</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>Influenza vaccine</keyword>
	<keyword>interferon</keyword>
	<keyword>adjuvant</keyword>
	<keyword>elderly</keyword>
</DOC>